Biogen (BIIB)
(Delayed Data from NSDQ)
$215.50 USD
+6.60 (3.16%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $215.67 +0.17 (0.08%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIIB 215.50 +6.60(3.16%)
Will BIIB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Stock Market News for Apr 25, 2024
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Other News for BIIB
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
The Analyst Landscape: 27 Takes On Biogen
Is Biogen Inc (BIIB) Set to Underperform? Analyzing the Factors Limiting Growth
Biogen (BIIB)'s Market Evaluation: A Fair Valuation Analysis
7 Retirement Stocks to Buy at a 52-Week Low in April